EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Clinical trials for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) trials appear
Sign up with your email to follow new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive lung cancer: Three-Drug cocktail trial
Disease control Recruiting nowThis study is testing whether adding different investigational drugs to standard chemotherapy works better for adults newly diagnosed with extensive-stage small cell lung cancer. Researchers will compare three treatment groups to see which combination is safest and most effective…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New cancer drug trial targets genetic weaknesses in tumors
Disease control Recruiting nowThis early-stage study is testing a new drug called IDE161, both alone and combined with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors that have spread. The main goals are to find safe doses and see if the treatment shows early signs of shrinkin…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for Tough-to-Treat lung cancer: experimental combo enters human testing
Disease control Recruiting nowThis early-stage study is testing the safety of a three-part treatment for extensive-stage small cell lung cancer that has persisted, returned, or worsened after standard therapy. The treatment combines a new drug called iadademstat with an existing immunotherapy (atezolizumab) a…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug trial targets aggressive lung cancer after standard treatments fail
Disease control Recruiting nowThis study is testing whether the drug teniposide can help control advanced small cell lung cancer that has worsened despite standard chemotherapy. It is for patients whose cancer has a specific genetic feature called 'c-Myc-driven.' The main goal is to see if the drug shrinks tu…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for aggressive lung cancer: trial tests Triple-Threat treatment
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug (tislelizumab) to standard chemotherapy, followed by targeted chest radiation, can better control advanced small cell lung cancer. The trial will enroll 36 newly diagnosed patients to see if this combination helps keep…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for Tough-to-Treat lung cancer: major trial tests promising drug
Disease control Recruiting nowThis study is testing whether a newer drug, sacituzumab govitecan, works better than the current standard treatments for people with extensive stage small cell lung cancer that has worsened after their first round of chemotherapy. About 695 participants will be randomly assigned …
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New Triple-Threat attack on aggressive lung cancer
Disease control Recruiting nowThis study is testing a new combination treatment for people newly diagnosed with extensive-stage small cell lung cancer, a fast-growing and aggressive form of the disease. It combines an immunotherapy drug (tislelizumab) with standard chemotherapy and radiation therapy. The main…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug duo aims to keep aggressive lung cancer in check
Disease control Recruiting nowThis study is testing if a combination of two drugs can help control cancer growth in adults with extensive-stage small cell lung cancer. The treatment is given as a long-term 'maintenance' therapy after initial chemotherapy. Researchers will measure success by seeing if tumors s…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Bindu R Potugari • Aim: Disease control
Last updated Mar 02, 2026 15:25 UTC